Press releases

Preliminary data in PREVAIL clinical trial met two out of three co-primary endpoints.

First presentation of the preliminary results of all three co-primary endpoints to be revealed during American College of Cardiology 2013 Annual Scientific Sessions.

New tool available to assist in the treatment of peripheral arterial disease.

Clinical presentations will provide new insights on Boston Scientific research in cardiovascular disease, including aortic valve disease and atrial fibrillation.

Boston Scientific will participate in the healthcare conference on February 26 in New York. Learn how to watch the webcast or replay.

Extensive sales resources, distribution network and service capabilities are expected to enable Boston Scientific to reach substantially more accounts, customers and patients in Japan.

Boston Scientific will participate in the healthcare conference on February 25 in New York. Learn how to watch the webcast or replay.

The next advance in durable polymer stent technology from Boston Scientific is now available in Europe and other select geographies.

Boston Scientific will participate in the healthcare conference on February 13 in New York. Learn how to watch the webcast or replay.

Organizations team up to raise awareness and make a call to action for European governments to develop comprehensive chronic pain treatment programs.

“I am confident we are taking the critical steps that are needed to return our company to long-term growth,” said president and CEO Mike Mahoney.

Boston Scientific will webcast its conference call with financial results and business highlights for Q4 and FY ended December 31. Learn how to tune in.

International, multi-center study focuses on patients with paroxysmal atrial fibrillation.

Learn how to tune in or watch the Investor Day replay.

A live webcast and replay will be available. Learn how to tune in.

Company begins evaluation of its next generation pacing leads.

Close the Gap initiative urges fans to learn their risk factors for heart disease.

World's first and only system with 32 contacts and 32 dedicated power sources is designed to provide pain relief to a broad spectrum of chronic pain patients.

Study to compare clinical outcomes of self-expanding metal stents (SEMS) versus plastic stents for the treatment of biliary strictures caused by chronic pancreatitis.

Stent system study to support FDA and Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions; received CE approval last month.

Devices projected to have up to twice the longevity of comparable products.

Company to consolidate Natick, Mass. headquarters into existing Marlborough site to create collaborative campus setting; to be completed by summer 2014.

MADIT-RIT clinical trial study results published today in the New England Journal of Medicine

Appointment completes company's CEO transition plan; Mahoney Replaces Interim CEO William H. (Hank) Kucheman.

Innovative bioabsorbable coating is the first to complete absorption shortly after drug elution ends at three months.